Cytovale
Laboratory Medicine
OVERVIEW: Cytovale is at the forefront of laboratory medicine innovation with its IntelliSep sepsis test, an FDA-cleared rapid diagnostic specifically designed for emergency departments. Addressing sepsis—the leading cause of death and the most expensive condition to treat in U.S. hospitals—IntelliSep provides a new standard for early detection by analyzing the immune system’s response to infection. This groundbreaking tool is transforming how sepsis is identified and managed.
IMPACT ACHIEVED: IntelliSep has demonstrated remarkable outcomes since its launch. At its first commercial site in Louisiana, patients tested with IntelliSep were treated 60–70 minutes faster and spent 1.4 less days in the hospital. The hospital also reduced unnecessary blood cultures by 2,000, saving valuable nurse time and preventing one sepsis-related death per week. The site also saved $1,400 per patient. These results have led to a system-wide rollout across Louisiana and Mississippi and fostered partnerships with health systems nationwide, with Cytovale projecting a tenfold increase in its footprint over the next year.
DISTINCTIVE EDGE: Cytovale’s innovative technology redefines sepsis detection by targeting immune system responses, cutting through clinical uncertainty with unparalleled accuracy. Beyond sepsis, Cytovale is exploring applications in other immune-mediated conditions, positioning itself as a leader in early detection technologies that transform patient care.